SHENZHEN, CHINA, Jan. 08, 2025 (GLOBE NEWSWIRE) -- China Medical System Holdings Limited (the 'Company”, together with its subsidiaries, the 'Group” or 'CMS”) is pleased to announce that on 8 January 2025, the Group through a wholly-owned subsidiary of the Company entered into a License, Collaboration and Distribution Agreement (the 'Agreement”) with Alpha Cognition Inc. ('Alpha”) of the improved new drug ZUNVEYL（benzgalantamine delayed-release tablets）('ZUNVEY” or the 'Product”) for the treatment of mild-to-moderate dementia of the Alzheimer's type. The Group is entitled to an exclusive right to develop, register, manufacture, import, export and commercialize the Product in Asia (excluding Japan), Australia and New Zealand (the 'Territory”), Alpha reserves the right to manufacture and supply in the Territory. The term of cooperation commences on the effective date of the Agreement and extends for twenty years, which may be automatically renewed every five years upon the expiration unless terminated by notice from either party.